An Open-label, Multicenter, Single-arm Clinical Study on the Use of Doxorubicin Liposome in Combination With CapOX and Bevacizumab Regimen for First-line Treatment of Advanced Colorectal Adenocarcinoma With SMAD4R361H/C Mutation.

NCT06753721 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

13

Enrollment

OTHER

Sponsor class

Conditions

Advanced Colorectal Adenocarcinoma

Interventions

DRUG: Doxorubicin liposome combined with CapOX and Bevacizumab

Sponsor

Nanfang Hospital, Southern Medical University